Wednesday , November 22 2017
Home / 2016 / May

Monthly Archives: May 2016

FDA Grants Accelerated Approval to BMS’ Opdivo for Classical Hodgkin Lymphoma

PRINCETON, N.J.–(BUSINESS WIRE)–Bristol-Myers Squibb Company (NYSE:BMY) today announced the U.S. Food and Drug Administration (FDA) has approved Opdivo®(nivolumab) for the treatment of patients with classical Hodgkin lymphoma (cHL) who have relapsed or progressed after autologous hematopoietic stem cell transplantation (auto-HSCT) and post-transplantation brentuximab vedotin.1 This accelerated approval is based on …

Read More »

Bayer and ERS Genomics Announce Licensing Agreement for Genome-Editing Patents

LEVERKUSEN, Germany & DUBLIN–(BUSINESS WIRE)–Bayer and ERS signed a patent license agreement whereby Bayer gains access to ERS’ CRISPR-Cas9 genome-editing patents for certain cross-divisional applications in Bayer’s core strategic areas. ERS Genomics holds rights to the foundational CRISPR-Cas9 patent portfolio from Dr. Emmanuelle Charpentier, an inventor of the breakthrough gene-editing …

Read More »

Biogen Collaborates with University of Pennsylvania to Advance Gene Therapy and Gene Editing Technologies

CAMBRIDGE, Mass.–(BUSINESS WIRE)–Biogen (NASDAQ:BIIB) today announced a broad collaboration and alliance with the University of Pennsylvania (“Penn”) to advance gene therapy and gene editing technologies. The expansive research and translational development collaboration has multiple objectives, but will primarily focus on the development of therapeutic approaches that target the eye, skeletal muscle and the central nervous system …

Read More »

FDA Expands Approval of Eisai’s Lenvima in Kidney Cancer

WOODCLIFF LAKE, N.J., May 13, 2016 /PRNewswire/ — Eisai Inc. announced today that the U.S. Food and Drug Administration (FDA) approved LENVIMA® (lenvatinib), the company’s multiple receptor tyrosine kinase inhibitor, in combination with everolimus for the treatment of patients with advanced renal cell carcinoma (aRCC) who were previously treated with an …

Read More »

FDA Advises to Avoid Cipro and Similar Drugs for Common Infections Due to Disabling Side Effects

The U.S. Food and Drug Administration is advising that the serious side effects associated with fluoroquinolone antibacterial drugs generally outweigh the benefits for patients with sinusitis, bronchitis, and uncomplicated urinary tract infections who have other treatment options. For patients with these conditions, fluoroquinolone should be reserved for those who do …

Read More »

Scientists Develop New Treatment to Prolong Life of Cystic Fibrosis Patients

Scientists at Queen’s University Belfast have discovered a new molecule which has the potential to prolong the life of individuals with cystic fibrosis (CF). The molecule represents a possible future treatment and works by altering cellular ion channels resulting in improved airway hydration and significantly increased mucous clearance. For individuals …

Read More »

European Commission Approves Opdivo in Combination with Yervoy for Treatment of Advanced Melanoma

PRINCETON, N.J.–(BUSINESS WIRE)–Bristol-Myers Squibb Company (NYSE:BMY) announced today that the European Commission (EC) has approved Opdivo in combination with Yervoy for the treatment of advanced (unresectable or metastatic) melanoma in adults, representing the first and only approved combination of two Immuno-Oncology agents in the European Union (EU). This approval allows …

Read More »